PMID- 27236448
OWN - NLM
STAT- MEDLINE
DCOM- 20170213
LR  - 20220330
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 39
DP  - 2016 Jul
TI  - Levetiracetam vs. brivaracetam for adults with refractory focal seizures: A 
      meta-analysis and indirect comparison.
PG  - 28-33
LID - S1059-1311(16)30031-0 [pii]
LID - 10.1016/j.seizure.2016.05.004 [doi]
AB  - PURPOSE: The study aimed to compare the efficacy and tolerability of 
      levetiracetam (LEV) and brivaracetam (BRV) in adults with refractory focal 
      seizures. METHOD: We systematically queried Medline, Embase, and the Cochrane 
      Library. We looked for additional studies in the references of all identified 
      publications and ClinicalTrials.gov. The cutoff day was November 6, 2015. 
      Randomized, double-blind, placebo-controlled trials were included. The indirect 
      comparison for 50% responder rate, seizure-free rate, and adverse effects were 
      conducted. RESULTS: Thirteen trials enrolling 1765 patients in the LEV group and 
      1919 patients in the BRV group were included. No statistically significant 
      differences were found in efficacy between LEV and BRV at various dose levels. 
      However, most risk ratios (RRs) at three dose levels and the overall RR were >1 
      for 50% response proportions. The majority of statistically significant 
      differences for adverse events and withdrawal of LEV and BRV were found at high- 
      and middle-dose levels. The indirect comparison of adverse effects (AEs) showed 
      statistically statistical differences in dizziness. CONCLUSION: Our results 
      suggested that LEV might have a slightly higher efficacy with a lower probability 
      of dizziness compared with BRV for patients with refractory focal seizures.
CI  - Copyright (c) 2016 British Epilepsy Association. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Zhang, Lin
AU  - Zhang L
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Li, Shaoping
AU  - Li S
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Li, Hua
AU  - Li H
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Zou, Xiaoyi
AU  - Zou X
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, China. 
      Electronic address: xiaoyizou@163.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20160516
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Anticonvulsants)
RN  - 0 (Pyrrolidinones)
RN  - 44YRR34555 (Levetiracetam)
RN  - U863JGG2IA (brivaracetam)
RN  - ZH516LNZ10 (Piracetam)
SB  - IM
MH  - Adult
MH  - Anticonvulsants/administration & dosage/adverse effects/*pharmacology
MH  - Epilepsies, Partial/*drug therapy
MH  - Humans
MH  - Levetiracetam
MH  - *Outcome Assessment, Health Care
MH  - Piracetam/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacokinetics
MH  - Pyrrolidinones/administration & dosage/adverse effects/*pharmacology
OTO - NOTNLM
OT  - Brivaracetam
OT  - Levetiracetam
OT  - Meta-analysis
OT  - Refractory focal seizures
EDAT- 2016/05/30 06:00
MHDA- 2017/02/14 06:00
CRDT- 2016/05/30 06:00
PHST- 2016/03/29 00:00 [received]
PHST- 2016/05/09 00:00 [revised]
PHST- 2016/05/10 00:00 [accepted]
PHST- 2016/05/30 06:00 [entrez]
PHST- 2016/05/30 06:00 [pubmed]
PHST- 2017/02/14 06:00 [medline]
AID - S1059-1311(16)30031-0 [pii]
AID - 10.1016/j.seizure.2016.05.004 [doi]
PST - ppublish
SO  - Seizure. 2016 Jul;39:28-33. doi: 10.1016/j.seizure.2016.05.004. Epub 2016 May 16.